Literature DB >> 21571674

Regional and temporal differences in gene expression of LH(BETA)T(AG) retinoblastoma tumors.

Samuel K Houston1, Yolanda Pina, Jennifer Clarke, Tulay Koru-Sengul, William K Scott, Lubov Nathanson, Amy C Schefler, Timothy G Murray.   

Abstract

PURPOSE: The purpose of this study was to evaluate by microarray the hypothesis that LH(BETA)T(AG) retinoblastoma tumors exhibit regional and temporal variations in gene expression.
METHODS: LH(BETA)T(AG) mice aged 12, 16, and 20 weeks were euthanatized (n = 9). Specimens were taken from five tumor areas (apex, anterior lateral, center, base, and posterior lateral). Samples were hybridized to gene microarrays. The data were preprocessed and analyzed, and genes with a P < 0.01, according to the ANOVA models, and a log(2)-fold change >2.5 were considered to be differentially expressed. Differentially expressed genes were analyzed for overlap with known networks by using pathway analysis tools.
RESULTS: There were significant temporal (P < 10(-8)) and regional differences in gene expression for LH(BETA)T(AG) retinoblastoma tumors. At P < 0.01 and log(2)-fold change >2.5, there were significant changes in gene expression of 190 genes apically, 84 genes anterolaterally, 126 genes posteriorly, 56 genes centrally, and 134 genes at the base. Differentially expressed genes overlapped with known networks, with significant involvement in regulation of cellular proliferation and growth, response to oxygen levels and hypoxia, regulation of cellular processes, cellular signaling cascades, and angiogenesis.
CONCLUSIONS: There are significant temporal and regional variations in the LH(BETA)T(AG) retinoblastoma model. Differentially expressed genes overlap with key pathways that may play pivotal roles in murine retinoblastoma development. These findings suggest the mechanisms involved in tumor growth and progression in murine retinoblastoma tumors and identify pathways for analysis at a functional level, to determine significance in human retinoblastoma. Microarray analysis of LH(BETA)T(AG) retinal tumors showed significant regional and temporal variations in gene expression, including dysregulation of genes involved in hypoxic responses and angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21571674      PMCID: PMC3176059          DOI: 10.1167/iovs.10-6321

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  40 in total

1.  Retinoblastoma incidence in the United States.

Authors:  D H Abramson
Journal:  Arch Ophthalmol       Date:  1990-11

2.  The incidence of retinoblastoma in the United States: 1974 through 1985.

Authors:  A Tamboli; M J Podgor; J W Horm
Journal:  Arch Ophthalmol       Date:  1990-01

3.  Retinoblastoma in transgenic mice.

Authors:  J J Windle; D M Albert; J M O'Brien; D M Marcus; C M Disteche; R Bernards; P L Mellon
Journal:  Nature       Date:  1990-02-15       Impact factor: 49.962

Review 4.  Tumor necrosis factor, cancer and anticancer therapy.

Authors:  Simone Mocellin; Carlo Riccardo Rossi; Pierluigi Pilati; Donato Nitti
Journal:  Cytokine Growth Factor Rev       Date:  2004-12-19       Impact factor: 7.638

5.  The incidence of retinoblastoma.

Authors:  S S Devesa
Journal:  Am J Ophthalmol       Date:  1975-08       Impact factor: 5.258

Review 6.  Microvascular corrosion casting in the study of tumor vascularity: a review.

Authors:  M A Konerding; A J Miodonski; A Lametschwandtner
Journal:  Scanning Microsc       Date:  1995

Review 7.  Mdmx and Mdm2: brothers in arms?

Authors:  Jean-Christophe Marine; Aart G Jochemsen
Journal:  Cell Cycle       Date:  2004-07-02       Impact factor: 4.534

Review 8.  Tumorigenesis and the angiogenic switch.

Authors:  Gabriele Bergers; Laura E Benjamin
Journal:  Nat Rev Cancer       Date:  2003-06       Impact factor: 60.716

9.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

Review 10.  Targeting the mTOR signaling network for cancer therapy.

Authors:  Funda Meric-Bernstam; Ana Maria Gonzalez-Angulo
Journal:  J Clin Oncol       Date:  2009-03-30       Impact factor: 44.544

View more
  7 in total

1.  The TAg-RB murine retinoblastoma cell of origin has immunohistochemical features of differentiated Muller glia with progenitor properties.

Authors:  Sanja Pajovic; Timothy W Corson; Clarellen Spencer; Helen Dimaras; Marija Orlic-Milacic; Mellone N Marchong; Kwong-Him To; Brigitte Thériault; Mark Auspitz; Brenda L Gallie
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-09-29       Impact factor: 4.799

2.  Evidence of Tumour Microenvironment and Stromal Cellular Components in Retinoblastoma.

Authors:  Rajeswari Raguraman; Sowmya Parameswaran; Jagat Rakesh Kanwar; Vikas Khetan; Pukhraj Rishi; Rupinder Kaur Kanwar; Subramanian Krishnakumar
Journal:  Ocul Oncol Pathol       Date:  2018-07-17

3.  Retinoblastoma treatment: impact of the glycolytic inhibitor 2-deoxy-d-glucose on molecular genomics expression in LH(BETA)T(AG) retinal tumors.

Authors:  Yolanda Piña; Samuel K Houston; Timothy G Murray; Tulay Koru-Sengul; Christina Decatur; William K Scott; Lubov Nathanson; Jennifer Clarke; Theodore J Lampidis
Journal:  Clin Ophthalmol       Date:  2012-05-29

4.  Optical coherence tomography enables imaging of tumor initiation in the TAg-RB mouse model of retinoblastoma.

Authors:  Andrea A Wenzel; Michael N O'Hare; Mehdi Shadmand; Timothy W Corson
Journal:  Mol Vis       Date:  2015-05-01       Impact factor: 2.367

Review 5.  Genetic causes of hypomagnesemia, a clinical overview.

Authors:  Daan H H M Viering; Jeroen H F de Baaij; Stephen B Walsh; Robert Kleta; Detlef Bockenhauer
Journal:  Pediatr Nephrol       Date:  2016-05-27       Impact factor: 3.714

6.  Intravitreal and subconjunctival melphalan for retinoblastoma in transgenic mice.

Authors:  Nisha V Shah; D G Pham; T G Murray; C Decatur; E Hernandez; Nikesh N Shah; M Cavalcante; S K Houston
Journal:  J Ophthalmol       Date:  2014-03-10       Impact factor: 1.909

7.  Targeting Notch signaling as a novel therapy for retinoblastoma.

Authors:  Laura Asnaghi; Arushi Tripathy; Qian Yang; Harpreet Kaur; Allison Hanaford; Wayne Yu; Charles G Eberhart
Journal:  Oncotarget       Date:  2016-10-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.